腺病毒重组人p53联合放化疗治疗局部晚期宫颈癌的疗效和安全性  

Efficacy and safety of recombinant human adenovirus-p53 injection combined with chemoradiotherapy in the treatment of locally advanced cervical cancer

作　　者：胡菊梅 徐丽丽 张俣 HU Ju-mei;XU Li-li;ZHANG Yu(Department of Gynecology,Jinhua Central Hospital,Zhejiang Jinhua 321000,China;Department of Gynecology,Jinhua Maternal and Child Health Hospital Jinhua,Zhejiang Jinhua 321099,China)

机构地区：[1]金华市中心医院妇科,浙江金华321000 [2]金华市妇幼保健院妇科,浙江金华321099

出　　处：《临床药物治疗杂志》2024年第5期44-48,共5页Clinical Medication Journal

摘　　要：目的探讨腺病毒重组人p53(rhAd-p53)联合放化疗治疗局部晚期宫颈癌(LACC)的疗效和安全性。方法选取2019—2021年金华市中心医院收治的LACC患者作为观察对象,随机分为观察组与对照组。对照组予以单纯放化疗,观察组予以rhAd-p53联合放化疗。分别于治疗前和治疗后,进行血清肿瘤标志物和黏蛋白1(MUC-1)、IL-33的测定;比较两组近期疗效、远期预后和不良反应发生情况。结果共纳入LACC患者120例,每组60例。治疗后,观察组客观缓解率为88.3%,高于对照组的70.0%(P<0.05)。观察组3年无进展生存率为74.0%,高于对照组的51.8%(P<0.05);两组3年总生存率比较,差异无统计学意义(83.2%比69.7%,P>0.05)。相比对照组,观察组血清癌胚抗原(CEA)、鳞状细胞癌抗原(SCC)、肿瘤特异性生长因子(TSGF)、MUC-1、IL-33水平均更低(P<0.05)。两组不良反应发生率差异无统计学意义(P>0.05)。结论rhAd-p53联合放化疗治疗LACC患者可获得较好疗效,能有效降低血清肿瘤标志物和IL-33、MUC-1水平,使患者远期生存获益,且不增加不良反应。Objective To investigate the efficacy and safety of recombinant human adenovirus-p53(rhAd-p53)injec⁃tion combined with chemoradiotherapy in the treatment of locally advanced cervical cancer(LACC).Methods LACC patients admitted to Jinhua Central Hospital from 2019 to 2021 were randomly divided into experimental group and control group.The control group was treated with chemoradiotherapy alone,and the experimental group was treated with rhAd-p53 combined with chemoradiotherapy.Serum tumor markers,mucin 1(MUC-1)and IL-33 were measured before and after treatment.The short term efficacy,long term survival prognosis,various indicators and the occurrence of adverse reactions were compared be⁃tween the two groups.Results A total of 120 LACC patients were included,with 60 patients in each group.The objective re⁃sponse rate in the experimental group was 88.3%,which was higher than that of the control group(70.0%)(P<0.05).The 3-year PFS rate in the experimental group was 74.0%,which was significantly higher than that of the control group(51.8%)(P<0.05).There was no significant difference in 3-year OS rate between the two groups(83.2%vs 69.7%,P>0.05).Com⁃pared with the control group,the levels of serum carcinoembryonic antigen(CEA),squamous cell carcinoma antigen(SCC),tumor-specific growth factor(TSGF),MUC-1 and IL-33 in the experimental group were lower(P<0.05)after treatment.There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion rhAdp53 injection combined with chemoradiotherapy in the treatment of LACC patients can obtain better curative effect,and can effectively reduce serum tumor markers and IL-33,MUC-1 levels,which can benefit patients'long-term survival without increasing adverse reactions.

关 键 词：腺病毒重组人p53注射液 局部晚期宫颈癌 黏蛋白1 白细胞介素-33 

分 类 号：R979.19[医药卫生—药品] R737.3[医药卫生—药学]